Table 2.
Outcomes by Continued Thienopyridine Therapy
| Outcome | Thienopyridine, N = 554, N (2‐Year KM Rate) | No Thienopyridine, N = 1545, N (2‐Year KM Rate) | Adjusted HR (IQR)a | Adjusted P Valuea |
|---|---|---|---|---|
| Coronary death | 2 (0.2) | 14 (0.9) | 0.43 (0.09–2.07) | 0.30 |
| CVD | 3 (0.4) | 21 (1.3) | 0.32 (0.08–1.19) | 0.090 |
| All‐cause death | 8 (1.4) | 28 (1.7) | 0.73 (0.30–1.75) | 0.48 |
| MI | 21 (2.9) | 52 (3.1) | 1.08 (0.61–1.90) | 0.79 |
| Stroke | 4 (0.8) | 16 (1.1) | 0.61 (0.18–2.07) | 0.43 |
| ARC definite ST | 4 (0.8) | 7 (0.4) | 0.82 (0.21–3.15) | 0.77 |
| ARC definite/probable ST | 4 (0.8) | 9 (0.5) | 0.68 (0.19–2.43) | 0.55 |
| CVD/MI | 24 (3.3) | 67 (3.9) | 0.95 (0.56–1.60) | 0.84 |
| CVD/MI/stroke | 25 (3.7) | 78 (4.7) | 0.86 (0.52–1.42) | 0.55 |
| TIMI medical attention bleeding | 11 (2.1) | 16 (0.9) | 0.91 (0.38–2.18) | 0.83 |
| TIMI major bleeding | 1 (0.2) | 5 (0.4) | 0.39 (0.04–3.88) | 0.43 |
| TIMI major/minor bleeding | 7 (1.3) | 10 (0.6) | 1.46 (0.48–4.45) | 0.51 |
| Any TIMI bleed | 18 (3.5) | 24 (1.4) | 1.25 (0.62–2.53) | 0.54 |
Abbreviations: ARC, Academic Research Consortium; CVD, cardiovascular death; HR, hazard ratio; IQR, interquartile range; KM, Kaplan‐Meier; MI, myocardial infarction; ST, stent thrombosis; TIMI, Thrombolysis In Myocardial Infarction.
Data are presented as n (%).
a
Propensity stratified.